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Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341 S325mice had signiﬁcantly poorer cGVHD scores than control
mice (WT BM cells intoWT recipients), suggesting the role of
host parenchymal tissue cell expression of B7H1 in cGVHD.
Taken together, the PD-1 axis, especially B7H1 expression on
recipients, regulates the frequency of IL-17+ IFNg+ T cells and
contributes to the pathogenesis of cGVHD.433
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Between September 2010 and June 2012, 15 patients with
SAA underwent HLA identical sibling donor SCT using Flu-
darabine 180 mg/m2 IV over 6 days and Cyclophosphamide
100 mg/kg IV over 2 days. Five patients had in addition
a single fraction of Total Body irradiation (TBI) 200 cGy.
Cyclophosphamide 50 mg/kg/day IV on day +3 and +4 was
the sole GVHD prophylaxis. G-CSF mobilized peripheral
blood stem cells (PBSC) was the graft source. Tenmales and 5
females with a median age of 25 years (range: 8 e 42) had
SCT. Median PBSC cell dose infused was 9.5 x 106 CD34/Kg
(range: 5.4 e 17.2). Thirteen engrafted (86.6%) with median
neutrophil and platelet engraftment of 15.4 days (range: 15-
17) and 16.6 days (range: 12-32) respectively. Grade IIeIV
GVHD seen in 3 patients (23%) at 42, 49 and 68 days post SCT.
Two responded to combination of cyclosporine and pred-
nisolone while one patient with grade IV GVHD expired 64
days post SCT. Of 11 evaluable patients, 4 (36.3%) developed
chronic GVHDwhich was limited in all. Two patients with de
novo chronic GVHD were managed with prednisolone alone.
Overall 7 patients (46.6%) have not required any immuno-
suppression after SCT while 3 have required immunosup-
pressive therapy for 114, 127 and 225 days respectively At
a median follow up of 11 months (range: 1 e 22), 11 (73.3%)
are alive and well including 7 patients who did not require
any immunosuppressive therapy following SCT. The use of
post transplant cyclophosphamide as GVHD prophylaxis
following sibling donor transplant for SAA is associated with
low rates of GVHD. A large number (46%) did not require any
immunosuppression post SCT. Larger studies are required to
understand the utility of this prophylaxis in sibling donor
transplants for aplastic anemia.434
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San Francsico, CAPersistence of mixed chimerism (MC) following myeloa-
blative HCT in pediatric hematologic malignancies is related
to a high risk of relapse. We initiated a prospective study of
FWI and DLI in patients with MC at 30 days post-transplant.
We are reporting preliminary results on 43 enrolled patients
with a mean age of 106.5(SD) years. Fifty-eight percent of
patients had myeloid malignancies, 40% lymphoid malig-
nancies and 2% had biphenotypic leukemia. Based on day +30
bone marrow and peripheral blood chimerism results, 26/43
(60%) patients were found to have MC, and were assigned to
the intervention arm of the study consisting of FWI and DLI;
12 patients (28%) had full donor chimerism (FDC) or early
graft-versus host disease (GVHD) and were assigned to
observation arm, and 5 (12%) could not be assigned to either
arm due to early death or relapse. FWI started at a median of
day +50 (range 40-85), and ended at a median of day +75.5
(range 49-113). Following FWI, 9 patients (35%) converted to
FDC. Of 17 patients who remained MC following FWI, 15
proceeded to DLI, 1 did not receive further intervention due
to GVHD and one relapsed prior to DLI. Acute GVHD devel-
oped in 3/26 (12%) patients undergoing FWI and in 9/12
(75%) of patients in the observation arm (P < .01). Two
patients undergoing intervention developed grade II aGVHD
which resolved and 1 developed grade IV aGVHD that pro-
gressed to fatal cGVHD of the lungs. In the observation arm, 2
patients developed grade I, 5 developed grade II, 2 developed
grade III, and 1 developed grade IV aGVHD. Chronic GVHD
developed in 6 patients (2 in the intervention and 4 in the
observation arm). One of 6 patients developed de novo
cGVHD, following DLI. The incidence of acute and/or chronic
GVHD was 15% in the intervention arm of the study. Toxic
death rate due to GVHD was 4%. There were 11 events (3
treatment-related deaths and 8 relapses). Mean follow-up of
living patients was 17.610 (SD) months. EFS for the entire
cohort was 717(SD)% and was not signiﬁcantly different
between the observation arm and the intervention arm. Ten
patients (23%) had evidence of disease by ﬂow or cytoge-
netics, at the time of HCT. Based on chimerism results, 4 were
assigned to the intervention arm, 3 to the observation arm,
and 3 could not be assigned to any arm of the study due to
early relapse or death. EFS was signiﬁcantly lower in patients
with positive disease prior to transplant than in those
without evidence of disease (EFS 2715% vs. 867%). Among
26 patients undergoing intervention, relapse was signiﬁ-
cantly more common (P ¼ .014) in patients with positive
disease pre-transplant. Our data indicate that post-trans-
plant immunomodulation is safe and has overall low GVHD
risk (15%). Our schedule of FWI was not adequate to prevent
relapse in patients coming to transplant with persistent
disease. We would recommend an earlier, (day 30) and more
aggressive schedule of immunosuppression withdrawal for
these patients.435
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Background: GVHD is still a major obstacle in allogeneic
transplantation despite the progress of immunosuppressive
drugs and cell therapy such as mesenchymal stem cells.
GVHD is caused by donor lymphocytes, mainly T cells,
